Literature DB >> 26525791

Effect of High-Dose Antimicrobials on Biofilm Growth of Achromobacter Species Isolated from Cystic Fibrosis Patients.

Sean K Tom1, Yvonne C W Yau2, Trevor Beaudoin1, John J LiPuma3, Valerie Waters4.   

Abstract

MICs and biofilm inhibitory concentrations (BICs) were measured for 68 cystic fibrosis (CF) Achromobacter isolates for amikacin, aztreonam, colistin, levofloxacin, and tobramycin. With the exception of colistin and levofloxacin, the remaining antibiotics had MIC90s, BICs at which 50% of the isolates were susceptible (BIC50s), and BICs at which 90% of the isolates were susceptible (BIC90s) equal to or above the highest concentrations tested. In a biofilm model, tobramycin was able to significantly increase killing of bacterial cells compared to controls, for intermediate-resistant strains only, at concentrations of 1,000 and 2,000 μg/ml.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26525791      PMCID： PMC4704188          DOI： 10.1128/AAC.02240-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.

Authors:  Frans De Baets; Petra Schelstraete; Sabine Van Daele; Filomeen Haerynck; Mario Vaneechoutte
Journal:  J Cyst Fibros       Date:  2006-06-21       Impact factor: 5.482

2.  In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Anina Ratjen; Yvonne Yau; Jillian Wettlaufer; Larissa Matukas; James E A Zlosnik; David P Speert; John J LiPuma; Elizabeth Tullis; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2014-10-27       Impact factor: 5.191

3.  Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.

Authors:  Kitty Wu; Yvonne C W Yau; Larissa Matukas; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.

Authors:  Julia Emerson; Sharon McNamara; Anne Marie Buccat; Kelly Worrell; Jane L Burns
Journal:  Pediatr Pulmonol       Date:  2010-04

5.  Susceptibility of Alcaligenes denitrificans subspecies xylosoxydans to beta-lactam antibiotics.

Authors:  K Mensah; A Philippon; C Richard; P Névot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

6.  Classification of Achromobacter genogroups 2, 5, 7 and 14 as Achromobacter insuavis sp. nov., Achromobacter aegrifaciens sp. nov., Achromobacter anxifer sp. nov. and Achromobacter dolens sp. nov., respectively.

Authors:  Peter Vandamme; Edward R B Moore; Margo Cnockaert; Charlotte Peeters; Liselott Svensson-Stadler; Kurt Houf; Theodore Spilker; John J LiPuma
Journal:  Syst Appl Microbiol       Date:  2013-07-24       Impact factor: 4.022

Review 7.  Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.

Authors:  James F Chmiel; Timothy R Aksamit; Sanjay H Chotirmall; Elliott C Dasenbrook; J Stuart Elborn; John J LiPuma; Sarath C Ranganathan; Valerie J Waters; Felix A Ratjen
Journal:  Ann Am Thorac Soc       Date:  2014-09

8.  Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients.

Authors:  A Lambiase; M R Catania; M Del Pezzo; F Rossano; V Terlizzi; A Sepe; V Raia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-01-31       Impact factor: 3.267

9.  Genetic Adaptation of Achromobacter sp. during Persistence in the Lungs of Cystic Fibrosis Patients.

Authors:  Winnie Ridderberg; Signe Maria Nielsen; Niels Nørskov-Lauritsen
Journal:  PLoS One       Date:  2015-08-27       Impact factor: 3.240

10.  Outbreak of Achromobacter xylosoxidans in an Italian Cystic fibrosis center: genome variability, biofilm production, antibiotic resistance, and motility in isolated strains.

Authors:  Maria Trancassini; Valerio Iebba; Nicoletta Citerà; Vanessa Tuccio; Annarita Magni; Paola Varesi; Riccardo V De Biase; Valentina Totino; Floriana Santangelo; Antonella Gagliardi; Serena Schippa
Journal:  Front Microbiol       Date:  2014-04-03       Impact factor: 5.640
View more
  10 in total

1.  Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model.

Authors:  Trevor Beaudoin; Sarah Kennedy; Yvonne Yau; Valerie Waters
Journal:  J Vis Exp       Date:  2016-12-14       Impact factor: 1.355

Review 2.  Achromobacter xylosoxidans and Stenotrophomonas maltophilia: Emerging Pathogens Well-Armed for Life in the Cystic Fibrosis Patients' Lung.

Authors:  Quentin Menetrey; Pauline Sorlin; Estelle Jumas-Bilak; Raphaël Chiron; Chloé Dupont; Hélène Marchandin
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

3.  Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis.

Authors:  R H V Pereira; R S Leão; A P Carvalho-Assef; R M Albano; E R A Rodrigues; M C Firmida; T W Folescu; M C Plotkowski; V G Bernardo; E A Marques
Journal:  Epidemiol Infect       Date:  2016-11-22       Impact factor: 4.434

4.  A Pan-Genomic Approach to Understand the Basis of Host Adaptation in Achromobacter.

Authors:  Julie Jeukens; Luca Freschi; Antony T Vincent; Jean-Guillaume Emond-Rheault; Irena Kukavica-Ibrulj; Steve J Charette; Roger C Levesque
Journal:  Genome Biol Evol       Date:  2017-04-01       Impact factor: 3.416

5.  Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance.

Authors:  T Beaudoin; Y C W Yau; P J Stapleton; Y Gong; P W Wang; D S Guttman; V Waters
Journal:  NPJ Biofilms Microbiomes       Date:  2017-10-19       Impact factor: 7.290

6.  A putative enoyl-CoA hydratase contributes to biofilm formation and the antibiotic tolerance of Achromobacter xylosoxidans.

Authors:  Lydia C Cameron; Benjamin Bonis; Chi Q Phan; Leslie A Kent; Alysha K Lee; Ryan C Hunter
Journal:  NPJ Biofilms Microbiomes       Date:  2019-08-06       Impact factor: 7.290

7.  Achromobacter Species Isolated from Cystic Fibrosis Patients Reveal Distinctly Different Biofilm Morphotypes.

Authors:  Signe M Nielsen; Niels Nørskov-Lauritsen; Thomas Bjarnsholt; Rikke L Meyer
Journal:  Microorganisms       Date:  2016-09-14

8.  Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms.

Authors:  Trevor Beaudoin; Tracy A Stone; Miroslawa Glibowicka; Christina Adams; Yvonne Yau; Saumel Ahmadi; Christine E Bear; Hartmut Grasemann; Valerie Waters; Charles M Deber
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

9.  First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due to Achromobacter Species with Literature Review.

Authors:  Nishant Tripathi; Niki Koirala; Hirotaka Kato; Tushi Singh; Kishore Karri; Kshitij Thakur
Journal:  Case Rep Gastrointest Med       Date:  2020-01-16

Review 10.  Microbiology of Cystic Fibrosis Airway Disease.

Authors:  Ana C Blanchard; Valerie J Waters
Journal:  Semin Respir Crit Care Med       Date:  2019-12-30       Impact factor: 3.119
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.